培美曲塞+顺铂与多西紫杉醇+替吉奥治疗晚期乳腺癌的效果比较

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (32 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To compare the effect of Pemetrexed+Cisplatin and Docetaxel+Tegiol in the treatment of advanced breast cancer.Methods All of 80 patients with breast cancer admitted to our hospital from March 2015 to July 2017 who met the inclusion criteria were retrospectively analyzed.The patients were divided into the Pemetrexed group(n=40)and Docetaxel group (n=40)according to the random number table method.Pemetrexed group was treated with Pemetrexed+Cisplatin,while Docetaxel group was treated with Docetaxel+Tegiol.The short-term efficacy,KPS score and adverse reactions in patients of the two groups were analyzed.Results Compared with before treatment,the KPS scores of both groups increased after treatment,and the differences were statistically significant(P＜0.05).There was no significant difference in KPS score between the two groups after treatment(P＞0.05).There were no significant differences in ORR and DCR between the two groups (P＞0.05).The main adverse reactions of the two groups were bone marrow suppression and gastrointestinal tract reaction,which could be alleviated after symptomatic supportive treatment.There were no significant differences in bone marrow suppression,gastrointestinal reaction,alopecia and rash classification between the two groups(Z=1.91,2.62,1.85,3.02,P＞0.05).Conclusion The clinical effect and safety of Pemetrexed+Cisplatin and Docetaxel+Tegiol in the treatment of advanced breast cancer have little difference.It can be selected according to the condition of breast cancer patients.

Key words： Pemetrexed Docetaxel Breast cancer Advanced stage

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Yan-cui
	ZHAO Wei
	SUN Ping
	SUN Cheng

Cite this article:

LIU Yan-cui,ZHAO Wei,SUN Ping, et al. Effect comparison of Pemetrexed+Cisplatin and Docetaxel+Tegiol in the treatment of advanced breast cancer[J]. 中国当代医药, 2019, 26(17): 33-35.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I17/33

[1]	张燕.以家庭为中心的护理干预对乳腺癌患者放射治疗依从性的影响[J].中国当代医药，2016，23（2）：188-190.
[2]	黄海平，张锦茹，李小芳，等.扶正消瘤汤联合紫杉醇治疗晚期乳腺癌的预后及肿瘤标志物含量、免疫功能评价[J].海南医学院学报，2016，22（20）：2467-2470.
[3]	郑向欣，管小青，吴骥，等.培美曲塞联合奈达铂治疗晚期乳腺癌的近期疗效[J].中国肿瘤外科杂志，2014，6（1）：12-15.
[4]	中华人民共和国卫生部医政司.乳腺癌诊疗规范（2011年版）[J].中国实用外科杂志，2011，31（10）：902-907.
[5]	杨学宁，吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学，2004，4（2）：85-90.
[6]	孙兴，冯关荣，韦世壮，等.胃肠肿瘤根治术后腹腔热灌注化疗联合微波热疗与静脉化疗的对比研究[J].广西医学，2016，38（2）：280-281.
[7]	李雅，张美丽，聂磊，等.培美曲塞联合顺铂治疗晚期转移性乳腺癌 26 例疗效观察[J].陕西医学杂志，2015，44（11）：1538-1539.
[12]	金小民，孙岩，李菁.卡培他滨联合多西紫杉醇对局部晚期乳腺癌患者的临床疗效及免疫功能的影响[J].中国基层医药，2017，24（10）：1543.
[13]	宋子琰，郑义同，卞宝祥.多西紫杉醇联合替吉奥治疗蒽环类耐药晚期乳腺癌的疗效观察[J].临床肿瘤学杂志，2012，17（2）：150-152.
[14]	陆筱灵，张永芹.培美曲塞联合顺铂治疗晚期乳腺癌疗效观察[J].医学理论与实践，2016，29（10）：1337-1338.
[15]	姚烜，李索妮，阮之平，等.紫杉醇脂质体与培美曲塞在乳腺癌细胞SK-BR-3中放疗增敏作用的比较及其机制[J].现代肿瘤医学，2015，23（16）：2256-2260.
[8]	朱慧婷，高嵩.托泊替康单药及与奥沙利铂联用治疗铂耐药性卵巢癌的临床研究[J].实用药物与临床，2016，19（2）：144-147.
[9]	黄红艳，江泽飞，王涛，等.卡培他滨单药或联合方案治疗晚期乳腺癌的疗效和安全性[J].中华肿瘤杂志，2011，33（11）：850-853.
[10]	张建东，邵震宇.多西紫杉醇联合卡培他滨治疗蒽环类耐药性晚期乳腺癌的疗效观察[J].中华肿瘤杂志，2008，30（10）：787-789.
[11]	戴武松，杨蓉，陈焕伟.多西紫杉醇联合卡培他滨治疗晚期蒽环类耐药三阴乳腺癌的临床观察[J].中国医药指南，2015，13（1）：121-122.